The impact of vitamin k2 supplementation on inhibition of vascular calcification in chronic kidney disease patients

Patients with chronic kidney disease (CKD) often have vascular calcification, which is defined by calcium deposition in the intimal and medial layers of the artery wall. Vascular calcification increases the risk of unfavorable cardiovascular (CV) outcomes. But our understanding of the intricate pathophysiology at play is still lacking. Vitamin K insufficiency is quite common in chronic kidney disease (CKD), and supplementing with this vitamin shows tremendous promise in slowing the onset of arterial calcification. The pathophysiology connecting vitamin K insufficiency and vascular calcification is covered in this article along with the functional vitamin K status in various stages of chronic kidney disease (CKD) and a review of recent research using animal models, observational studies, and clinical trials. The abnormal ectopic mineralization of the heart valves and artery walls is sometimes referred to as "cardiovascular calcification." However, a variety of pathophysiological pathways can contribute to the deposition of calcium across different cardiac and arterial beds, and the diverse manifestations of calcification result in distinct clinical problems. There are currently no authorized medicinal approaches for treating or preventing cardiovascular calcification. Clinical trials to examine the effectiveness of treatments may be complicated by the long-term development of calcification in cardiac and vascular tissues in the general population. People with chronic kidney disease (CKD) are a population in need of anticalcification treatments that might potentially finish clinical trials because of how quickly calcification develops in response to renal insufficiency.